Patient-specific pluripotent stem cells in doxorubicin cardiotoxicity: A new window into personalized medicine

Daniel Bernstein*, Paul Burridge

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

In the past ten years, there has been a revolution in our ability to generate human pluripotent stem cells (hiPSCs) from adult somatic cells. hiPSCs can be differentiated into many cell types, including cardiomyocytes (hiPSC-CMs), providing cardiovascular scientists for the first time with a human heart muscle cell line. hiPSC-CMs have several potential uses: to study mechanisms of disease, as a platform for screening drugs for efficacy and toxicity, and as cell therapy for diseases such as cardiomyopathy. In this review, we discuss the potential of using hiPSC-CMs for drug toxicity testing, and in particular to screen genetic variants found to be predictive of which patients develop cardiotoxicity after receiving the chemotherapeutic agent doxorubicin.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalProgress in Pediatric cardiology
Volume37
Issue number1-2
DOIs
StatePublished - Dec 1 2014

Keywords

  • Cancer
  • Cardiomyocytes
  • Doxorubicin cardiotoxicity
  • ROS
  • Stem cells

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Patient-specific pluripotent stem cells in doxorubicin cardiotoxicity: A new window into personalized medicine'. Together they form a unique fingerprint.

Cite this